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INTRODUCTION
Malignant tumors are the leading cause of death in the gen-
eral population worldwide. Although cardiovascular disease
is the most common cause of death in patients with chronic
kidney disease (CKD) (1, 2), the incidence of malignant dis-
eases is growing in this population due to increased life span.
Many studies have reported that patients who received kid-
ney transplant are at higher risk of malignant disease (3-6).
However, whether CKD patients undergoing dialysis treat-
ment have similar risks of developing malignancies is still
controversial (6-10), although most studies have shown that
this risk of developing malignant disease in CKD patients
(with or without dialysis) is increased in comparison with
the general population (3-13%) (3, 7, 11). The exact mech-
anisms responsible for this increased incidence of cancer have
not yet been fully elucidated but several factors such as im-
paired immune system, chronic infections, decreased antiox-
idant capacity, accumulation of carcinogenic compounds,
and dialysis-related factors may promote malignant trans-
formation and tumor formation (12-16).
As studies of cancer in CKD patients on dialysis in Korea
have not yet been reported, we undertook this study to inves-
tigate the clinical features and outcomes of cancer in Korean
dialysis patients.
MATERIALS AND METHODS
We conducted a retrospective study of a total of 4,562 end-
stage renal disease (ESRD) patients who started hemodialy-
sis (HD) or peritoneal dialysis (PD) at two centers at Yonsei
University (Shin-chon and Young-Dong Severance Hospi-
tal) from January 1996 to December 2005. Among the study
population, malignant diseases were diagnosed in 106 patients
(2.3%). Malignancies were detected by imaging methods
such as computed tomography (CT) or magnetic resonance
imaging (MRI) and by histological methods. Patients who
developed malignancies prior to dialysis or who received kid-
ney transplant were excluded. Medical records were reviewed
and used to collect data such as gender, age, underlying renal
diseases, and the interval from the initiation of dialysis to
the development of a malignant tumor. The cause of death
and age at the time of death of the ESRD patients with can-
cer were obtained from the Korea National Statistical Office.
For comparison with the general population, the medical
records of 53,720 patients diagnosed with cancer during the
same period at our hospital were also examined. This group
did not include CKD patients (with or without dialysis).
All data were expressed as mean±SD. Statistical analysis
was performed using Student’s t-test and the chi-square test,
and a value of p<0.05 was considered to indicate significant
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Cancer in Patients on Chronic Dialysis in Korea
The study of cancer in patients treated with dialysis in Korea has not been report-
ed. The aim of this study was to investigate the incidence and mortality of cancer
among patients on dialysis in Korea. The study subjects were 106 cancer patients
(2.3%) out of 4,562 end-stage renal disease (ESRD) patients maintained on hemodial-
ysis (HD) or peritoneal dialysis (PD) at Yonsei University Health System from 1996
to 2005. We excluded patients in whom the diagnosis of cancer preceded dialysis
or those who received renal allograft or started dialysis after renal allograft. Seven-
ty-three (69%) of our subjects were male and 33 (31%) were female. The mean age
at the time of cancer diagnosis was 57.9± ±11.7 yr. The mean time from the start of
dialysis to the diagnosis of cancer was 75.2± ±63.9 months. The most common can-
cer site was gastrointestinal tract (GIT) (51%) followed by urinary tract (20%), lung
(8%), and thyroid (7%). Sixty nine percent of the total mortality was due to cancer.
The mean time from diagnosis to death was 2.9± ±2.5 yr. In ESRD patients with can-
cer, there were no significant differences in mortality rates by dialysis modality. In
ESRD patients, the most common cancer was GIT cancer followed by urinary tract
cancer. Therefore, careful surveillance of these cancers in ESRD patients is highly
recommended.
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Accepted : 24 December 2008difference. The significance of differences in survival rates be-
tween HD and PD patients was determined using the Kaplan-
Meier method. The standardized incidence rate (SIR: the ratio
of observed to expected cancers) was used to estimate the rel-
ative risk and 95% confidence interval (CI) for these ratios
were calculated with the assumption that the observed num-
ber of cancer cases followed a Poisson distribution. Data analy-
sis was done with SAS software (version 6.12).
RESULTS 
Cancer in the general population (2002 annual report of
the Korea central cancer registry)
Of the total of 66,025 patients with malignancies regis-
tered from January 1 to December 31, 2002, 55,398 (55.9%)
cases were male and 43,627 (44.1%) cases were female: a
sex ratio of 1.27:1. The leading age groups in order of rela-
tive frequency were 60-64 yr of age (14.8%), followed by
65-69 (14.4%), 55-59 (11.7%), 70-74 (10.7%), 50-54 (9.9
%), and 45-49 (9.0%). The relative frequencies of age groups
below 45 and above 75 were 0.1-7.5% and 10.9%, respec-
tively. The leading primary cancer sites in order of relative
frequency were stomach (20.2%), followed by bronchus and
lung (11.9%), liver and intrahepatic bile ducts (11.3%), col-
orectum (11.2%), breast (7.4%), thyroid (4.9%), uterine
cervix (4.0%), hematopoietic systems (2.6%), pancreas (2.4
%), and urinary bladder (2.2%).
In males, the leading primary cancer sites were stomach
(24.0%), followed by bronchus and lung (15.0%), liver and
intrahepatic bile ducts (15.4%), colorectum (11.6%), urinary
bladder (3.2%), prostate (3.0%), esophagus (2.8%), hema-
topoietic systems (2.7%), pancreas (2.5%), and kidney (2.0%).
In females, breast (16.8%) was the most common site, fol-
lowed by stomach (15.3%), colorectum (10.7%), thyroid
(9.5%), uterine cervix (9.1%), bronchus and lung (6.6%),
liver and intrahepatic bile ducts (6.0%), ovary (3.6%), hema-
topoietic systems (2.5%), and pancreas (2.3%).
Cancer in the general population (from our hospital)
The mean age of the general population at the time of the
diagnosis of a malignant tumor was 53.0±18.1 yr (male:
female=28,335:25,385). The most common cancer was gas-
trointestinal tract (GIT) cancer (44%), followed by genital
organ cancer (18%), lung cancer (9%), thyroid cancer (7%),
and urinary tract cancer (4%). The remaining cancers were
head and neck cancer (4%), hematologic cancer (3.3%), skin
cancer (1%), and cancer of unknown origin (Fig. 1). 
Baseline characteristics of ESRD patients with cancer
Among the 4,562 ESRD patients, 106 (2.3%) were diag-
nosed with malignant tumors. Seventy three patients were male
(69%) and 33 were female (31%) (2.2:1). Unlike in the gen-
eral population, malignancies developed predominantly in the
males of our study population (p<0.05). Diabetic nephropa-
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GIT cancer 44%
The others 18%
Urinary tract
cancer 4%
Genital organ 
cancer 18%
Lung cancer 
9%
Thyroid 
cancer 7%
Fig. 1. Types of cancer in the general population (%).
*, age the time of diagnosis of cancer.
ESRD, end-stage renal disease; HD, hemodialysis; PD, peritoneal dial-
ysis; GN, glomerulonephritis.
Total ESRD patients
(n=4,562)
ESRD patients with
cancer (n=106)
Age* 50.7±14.6 (18-90) 57.9±11.7 (26-83)
Sex (M:F) 2760:1802 (1.5:1) 73:33 (2.2:1)
Dialysis mode (%)
HD  3011 (66) 63 (59)
PD 1551 (34) 43 (41)
Cause of ESRD (%)
DM 2,052 (45) 44 (42)
Hypertension 912 (20) 19 (18)
Chronic GN 821 (18) 17 (16)
Others 319 (7) 6 (5)
Unknown 458 (10) 20 (19)
Time to discovery of  75.2±63.9 (3-288)
cancer (months)
Table 1. Baseline characteristics of patients
GIT cancer 51%
The others 10% Genital organ 
cancer 4%
Urinary tract
cancer 20%
Lung cancer 
8%
Thyroid 
cancer 7%
Fig. 2. Types of cancer in ESRD patients (%).thy (42%), hypertensive nephropathy (18%), and chronic
glomerulonephritis (16%) were the most common causes of
ESRD. Among the 106 patients, 63 (59%) received HD, and
43 received PD (41%). The mean age at the time of diagnosis
of the cancer was 57.9±11.7 yr (26-83 yr), higher than the
general population (57.9±11.7 vs. 53.0±18.1 yr, p<0.05).
The mean duration from the initiation of dialysis to diagnosis
was 75.2±63.9 months (3-288 months) (Table 1). Follow-
up duration from diagnosis was 42.9±47.3 months (1-240).
In ESRD patients, GIT cancer was the most common fol-
lowed by urinary tract cancer, lung cancer, thyroid cancer,
hematologic cancer, genital tract cancer, head and neck can-
cer, and the others (Fig. 2, Table 2).
Comparison of cancer sites between the general 
population and ESRD patients
In the general population, common cancer sites were stom-
ach (22.0%), liver (16.3%), lung (12.3%), and intestine (10.8
%) in males, whereas in females, the incidence of female geni-
tal tract cancer, including uterine cervical cancer (19.4%)
and breast cancer (17.9%), was the highest, followed by stom-
ach (12.0%), thyroid (13.2%), and intestine (7.7%). On the
other hand, in ESRD patients, liver was the most common
cancer site followed by intestine and stomach in male patients.
In female patients, urinary tract cancer showed the highest
incidence rate (Table 3).
The time to the development of cancer in ESRD patients
The earliest diagnosed cancer was multiple myeloma and
the latest was cancer of liver (mainly hepatocellular carcinoma,
HCC). For cancer of liver, kidney and thyroid, the interval to
diagnosis of malignant tumors was relatively long (Table 4).
Among the 106 patients, 18 (17%) were diagnosed with
malignant tumors within 1 yr of beginning dialysis, and
the remaining 88 (83%) were diagnosed within 10 yr (Table
5). The risk of cancer was slightly higher when cancer was
diagnosed during the first year of dialysis. 
When ESRD patients were divided into two groups accord-
ing to age of 40, most malignancies developed after 40 yr of
age (84%);  Malignancies of patients older than 40 yr (n=89)
includes 47 GIT cancers, 14 urinary tract cancer, 9 lung can-
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*, mean time from the start of dialysis to the diagnosis of cancer.
ESRD, end-stage renal disease.
Location (n, %) Cancer type (n)
Gastrointestinal tract (54, 51%) Stomach (13)
Liver (20)
Intestine (16)
Pancreatobiliary (5)
Urinary tract (21, 20%) Kindey (12)
Bladder (9)
Lung (9, 8%) Lung (9)
Thyroid (8, 7%) Thyroid (8)
Genital tract (4, 4%) Uterine (2)
Ovary (1)
Prostate (1)
Hematologic (3, 3%) Multiple Myeloma (3)
Head & Neck (3, 3%) Tongue (1)
Larynx (1)
Mandibular (1)
Skin (1, 1%) Melanoma (1)
Others (3, 3%) Unknown origin (1)
Retroperitoneal tumor (1)
Malignant fibroma (1)
Table 2. Cancer types of ESRD patients
Type of cancer Mean Interval (months)
Liver 90.4±70.6 (19-288)
Colorectal 47.3±51.1 (5-168)
Stomach 57.6±43.8 (6-156)
Kidney 142.7±68.2 (60-276)
Bladder & Ureter  59.1±49.3 (14-154)
Lung 30.6.1±24.3 (4-69)
Thyroid 88.0±31.4 (27-123)
Hematologic 3.3±0.6 (3-4)
Table 4. Mean interval* to discovery of cancer in ESRD patients
ESRD, end-stage renal disease; SIR, standardized incidence rate; CI,
confidence interval.
ESRD, end-stage renal disease.
ESRD, end-stage renal disease.
Time after dialysis SIR (95% CI) n
During year 1  18 1.3 (1.0-1.4)
During year 2 14 1.1 (1.0-1.2)
During year 3-5 23 1.2 (1.1-1.3)
During year 6-10 32 1.3 (1.0-1.4)
After year 10 19 1.1 (1.0-1.2)
Table 5. Overall risk of cancer in ESRD patients by length of
dialysis treatment
Site
General population
M (28,335) F (25,221)
ESRD patients
M (73) F (33)
Stomach 6,234 (22%) 3,056 (12.0%) 11 (15%) 2 (6.1%)
Liver 4,611 (16.3%) 1,141 (4.5%) 17 (23.3%) 3 (9.1%)
Intestine 3,055 (10.8%) 1,976 (7.7%) 13 (17.8%) 3 (9.1%)
Esophagus 700 (2.5%) 56 (0.2%) 0 0
Pancreatobiliary 1,651 (5.8%) 1,175 (4.6%) 4 (5.5%) 1 (3.0%)
Lung 3,474 (12.3%) 1,246 (4.9%) 5 (6.8%) 4 (12.1%)
Thyroid 500 (1.8%) 3,369 (13.2%) 2 (2.7%) 6 (18.2%)
Urinary tract 1,537 (5.4%) 514 (2.0%) 11 (15.1%) 10 (30.3%)
Hematologic 1,003 (3.5%) 747 (2.9%) 2 (2.7%) 1 (3.0%)
Uterus 4,956 (19.4%) 2 (6.1%)
Breast 4,578 (17.9%) 0 (0%)
Testis & prostate 936 (3.3%) 1 (1.3%)
Table 3. Comparison of cancer sites between the general pop-
ulation and ESRD patientscers, 4 thyroid cancers, and 15 other cancers. In patients less
than 40 yr of age (n=18), there were 7 GIT cancer, 7 urinary
tract cancer, and 4 thyroid cancers (Fig. 3A). In the general
patients older than 40 yr, the leading primary cancer sites
were GIT (45%), followed by breast & uterine cervix (19%),
lung (9%), and thyroid (7%). In the general patients younger
than 40 yr, breast & uterine cervix (30%) was the most com-
mon site, followed by GIT (22%), thyroid (15%), and hema-
tologic systems (5%) (Fig. 3B).
Comparison of cancer types according to dialysis 
modality in ESRD patients
Fig. 4 shows the cancer distribution with respect to dialysis
modality. We found no significant difference between HD
and PD treated patients. In HD (n=63) patients, GIT can-
cer was the most common (n=37, 58.7%), followed by uri-
nary tract cancer (n=12, 19%) and lung cancer (n=4, 6.3%),
with a similar pattern seen in PD (n=43) patients. 
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Cancer sites 
(n=34, 60%)
nn Not related to cancer
(n=22, 40%)
Biliary tract  4/4 (100%)
Hematologic 2/3 (67%)
Lung 5/9  (56%)
Stomach 6/13 (46%)
Bladder 4/9 (44%)
Colorectal 5/15 (33%)
Liver 5/20 (25%)
Other cancer sites 13
Unknown 13
Cerebrovascular accident  3
Cardiovascular accident 3
Sepsis 2
Trauma 1
Others 3
Table 6. Mortality cause of ESRD patients with cancer
Fig. 3. Frequency of cancer by age between ESRD patients and general population. (A) ESRD patients, (B) general population.
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Fig. 4. Frequency of cancer by dialysis mode in ESRD patients.
Fig. 5. Survival of ESRD patients with cancer. (A) Comparison of survival rate between ESRD patients without cancer and ESRD patients
with cancer, (B) Comparison of survival rate by dialysis modality in ESRD patients with cancer.
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ESRD, end-stage renal disease.Survival of ESRD patients with cancer
The mean time from diagnosis to death was 2.9±2.5 yr.
Among the 106 cancer patients, the overall mortality rate
was 53%. Thirty four patients (60%) died of cancer and 22
(40%) died of cause not related to cancer, such as cerebral
hemorrhages (n=3), cardiovascular disease (n=3), sepsis (n=2),
trauma (n=1) and unknown reasons (n=13). Deaths occurred
in all patients with cancer of biliary tract system, in 2 out of
3 patients with hematologic cancer (67%), in 5 out of 9 pa-
tients with lung cancer (56%), and in 6 out of 13 patients
with bladder cancer (46%) (Table 6). 
The survival rate of ESRD patients without cancer was sig-
nificantly higher compared to that of ESRD patients with
cancer (p<0.05). In ESRD patients with cancer, there were
no significant differences in mortality rates by dialysis modal-
ity (Fig. 5). Five year survival rate was 44.0% and 46.6% in
patients treated with HD and PD respectively. 
DISCUSSION
CKD patients have a high incidence of cancer for several
reasons, including: weakened immune system, previous imm-
unosuppressive treatment, altered DNA repair, and chronic
infection (12-16).
In 25,044 patients who received dialysis in the U.S.A.,
Europe, Australia, or New Zealand, the overall risk of can-
cer is increased (3%) compared with the general population
(17). In one report, HD patients have a greater risk of devel-
oping malignant tumors than the general population, with
malignancies diagnosed in 4.9% of patients (18). In a recent
meta-analysis of 15 studies, it was found that the relative
risk (observed cancer cases over expected cancer cases) aver-
aged 7.6 in 10 studies (72,484 ESRD patients). In contrast,
in the remaining 5 studies (35,407 ESRD patients) the aver-
age risk was 0.98 (19). Despite this lack of consensus, there
is general agreement that CKD patients have a greater risk
of cancer than the general population. A recent report showed
that cancer incidence is increasing in Korea, with an incidence
rate of 242.3 per 100,000 (0.24%) for men from 1998 to
2002 (20). In our study, 106 (2.3%) organ tumors were found
in 4,562 CKD patients, which is a higher incidence of can-
cer compared with the general population, consistent with
previous reports. However, we also found the incidence of
malignancies in ESRD patients to be lower than in previous
reports (3-13%) (3, 7, 11). Although we have no clear expla-
nation for this discrepancy, it may partly be explained by our
research having been conducted more recently and, possibly,
differences in institution size and race. 
In 2002 annual report of the Korea central cancer registry,
the leading cancer site was stomach followed by lung and
liver in males whereas it was breast followed by stomach,
colorectum, and thyroid in females. On the other hand, in
ESRD patients, the most common cancer sites were liver,
colorectum, and urinary tract in males and urinary tract, thy-
roid, and lung in female in descending order.
Several previous studies (7, 21) have reported that urolog-
ic malignancies, which are not that common in the general
population, are the most common cancer in chronic hemodial-
ysis patients as well as nondialysed uremic patients. Cengiz
et al. (22) reported that 19% of CKD patients (regardless of
dialysis treatment) had a urologic malignancy. In other reports,
bladder cancer developed in 28.5% of HD patients (23) and
kidney and bladder cancers (12 of 33) were the most com-
mon types of cancer in HD patients (5). Ishikawa et al. (24)
also showed that the incidence of renal cell carcinoma in HD
patients was 41 times that of the general population. In con-
trast, our study found GIT cancers to be the most common
in ESRD patients, although urologic malignancy were more
prevalent than in the general population, which is similar to
the findings of a Japanese survey (25). In fact, these results
are not surprising, as stomach cancer is the most frequent in
Japan and Korea. 
The mean age at the time cancer diagnosis in ESRD pati-
ents was higher than in the general population. This may be
because the age of dialysis patients is relatively higher than
the general population as a whole, thus causing the age at
the time of cancer diagnosis to also be high. According to
the incidence rate by the dialysis duration, 17% of all malig-
nancies occurred within 1 yr of starting dialysis, with a grad-
ually decreasing trend in the malignancy incidence rate after-
wards. This finding was in line with a report by Inamoto et
al., reporting that the incidence was very high during the
first 6 months of dialysis treatment and rather low in the 7th-
10th year. (25). However, compared to the study by Inamo-
to et al, only 17% of all malignancies occurred within 1 yr
of starting dialysis in our study. This is partly because that
our study include many cases of HCC, thyroid cancer, etc.,
which generally have a relatively delayed development, and
that could explain why we found relatively few malignancies
within 1 yr of beginning dialysis. The risk of cancer was slight-
ly higher when cancer was diagnosed during the first year of
dialysis. This finding might be due to increased detection of
cancer and more detailed observation at the time of initial
dialysis treatment.
Similar to the general population, GIT cancers were the
most common in our subjects, implying that early detection
and aggressive treatment of these cancers is just as impor-
tant in ESRD patients as in the general population. In addi-
tion, the incidence of urinary tract cancer was substantially
higher than in the general population, indicating that it is
important to perform screening tests for this type of cancer
as well. Unlike in transplant recipients (26-28), the types of
cancers most commonly diagnosed in patients on dialysis
are those most likely to be found in the general non-ESRD
population. These results should reinforce the need for rou-
tine check-up to include renal and gastrointestinal tract can-
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Increased surveillance should lead to detection of cancers at
an earlier stage, which are not observed among GIT and uri-
nary tract cancers. 
Our findings showed that liver cancers were more preva-
lent in ESRD patients. Infection with HBV or HCV is a seri-
ous problem in dialysis patients. The fact that ESRD patients
have greater exposure to hepatitis B and C viruses than nor-
mal patients, probably accounts for the observed excess of
liver cancer (29). Therefore, widespread screening for HBV
and HCV also should be encouraged. 
It should be noted that all 3 hematologic malignancies
which occurred in ESRD patients were multiple myeloma.
Multiple myeloma (MM) is a common hematologic malig-
nancy and also can be the cause of ESRD (30). Consequent-
ly, the diagnosis of MM might be missed at the time of the
dialysis start and it is possible that its incidence could be
underestimated.
Interestingly, in our study, thyroid cancer was fairly com-
mon, it was found in 8 (7.5%) patients. Thyroid disease,
including hypothyroidism, goiter, nodules, and thyroid can-
cer, may occur more frequently in ESRD patients than in
the general population (17, 31), and it has been suggested
that chronic immunosuppression and secondary hyperparathy-
roidism may play a role (32, 33). 
There are several limitations to the present study. First,
we analyzed limited data from two centers in a retrospective
review. Second, we had more limited follow-up and fewer
observed cancer cases than those might be found in a larger
cohort of dialysis patients. Third, the relationship between
the underlying disease and malignancy was not evaluated.
However, even with such limitations, this study contributes
to a comprehensive assessment of cancer risk in ESRD pati-
ents, especially in Korea. 
In conclusion, our data shows that ESRD patients in Korea
have a higher risk of developing cancer than the general pop-
ulation, and the types of cancer most commonly diagnosed
in ESRD patients are those most likely to be found in the
general population. In addition, the incidence of urinary tract
cancer is higher in ESRD patients compared to the general
population, thus, careful surveillance for malignancies in
ESRD patients, especially for those of the urinary tract, is
highly recommended.
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